Get 15% Off on Memorial Day Sitewide Sale Get 15% Off on Memorial Day Sitewide Sale

ADVERTISEMENT

New Charges of Fraud on Heels of Abbott’s $1.5 Billion Plea Agreement

Marketing Fraud

Story at-a-glance -

  • Earlier this year, Abbott settled for $1.6 billion for aggressively promoting their seizure drug Depakote to physicians for off-label use in elderly dementia patients, despite lacking evidence of safety or effectiveness.
  • Just weeks later, Abbott is in the hot seat again after a former Abbott saleswoman filed a federal lawsuit against them, alleging the company illegally promoted the drug TriCor for uses not approved by the FDA, such as preventing cardiac health risks in patients with diabetes.
  • In most cases, a billion-dollar (or more) fraud settlement would be a death-sentence for a business, but for the drug industry, it's just another cost of doing business – and not enough to deter them from deliberately engaging in illegal practices.
  • The leading pharmaceutical companies are also among the largest corporate criminals in the world, behaving as if they are little more than white-collar drug dealers; you need to weigh the risks of using their products very carefully, as these companies consistently put profits above human health.

By Dr. Mercola

Only weeks after pleading guilty to criminal charges that it promoted its anti-seizure drug Depakote for uses not approved by the U.S. Food and Drug Administration (FDA), Abbott Labs is being sued again for similar charges with a different drug.


Read the Full Article for Free!
Subscribe to the #1 Natural Health Newsletter
  • Unlock censored health information that Google doesn't want you to read
  • Keep your privacy secure — We are no longer active on Facebook and will soon be blocking our content from Google search to ensure your privacy stays protected
  • Get access to all of Dr. Mercola's health articles, E-books and special reports

Existing Subscribers: Enter your email address for instant access

You can unsubscribe at any time and I guarantee the privacy of your email. View our privacy policy